Friends of Cancer Research (Friends) is excited to present data from three current projects at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. These findings are catalyzing meaningful improvements in oncology drug development and informing regulatory policy and patient care.
Saturday, June 3, 2023 | 8:00 AM-11:00 AM
Circulating tumor DNA (ctDNA) shows promise as an early endpoint to support drug development and regulatory decision-making. In a retrospective analysis of 8 clinical trials in patients with advanced non-small cell lung cancer (aNSCLC) treated with tyrosine kinase inhibitors (TKIs), non-detected ctDNA within the first 10 weeks of treatment was associated with the best outcomes (i.e., progression-free and overall survival) compared with having detected ctDNA. These findings suggest ctDNA can be used to assess response to treatment in patients treated with TKIs as early as 10 weeks after start of therapy.
This project was conducted in collaboration with Agilent Technologies, AstraZeneca, Bayer, Biodesix, Bio-Rad Laboratories, Inc., Boehringer Ingelheim, Bristol Myers Squibb Company, Cancer Research And Biostatistics (CRAB), Clovis Oncology, Inc., EMD Serono, Inc. (Merck KGaA), European Organisation for Research and Treatment of Cancer (EORTC), FDA, Foundation Medicine, Inc., Genentech, Inc., Guardant Health, Inc., Illumina, Inc., Johns Hopkins University School of Medicine, Loxo@Lilly, MD Anderson Cancer Center, Molecular Characterization Laboratory (MoCha) at Frederick National Laboratory, Natera, Inc., NMD Group LLC, Novartis AG, Pfizer, Princess Margaret Cancer Centre, Regeneron Pharmaceuticals Inc., Roche Diagnostics, and Takeda Pharmaceutical Company.
Saturday, June 3, 2023 | 1:15 PM-4:15 PM
Clinical trials often measure response data as an early indication of treatment activity. However, measurement of response in clinical trials often differs from the real-world setting. An analysis across seven electronic health data aggregators assessed the availability of data attributes to measure rw-response and evaluated the consistency of the measure across RWD sources. The measure was consistent across data sources and demonstrated the feasibility of measuring rw-response based on clinician assessments.
This project was conducted in collaboration with ASCO, ConcertAI, COTA, FDA, Flatiron Health, Guardian Research Network, IQVIA, Ontada, Syapse, and Tempus.
Monday, June 5, 2023 | 1:15 PM-4:15 PM
The COVID-19 pandemic disrupted enrollment and conduct of cancer treatment trials. As a result, regulators encouraged flexibility to trial processes to enable clinical research and care to continue. An analysis of surveys and interviews with pharmaceutical companies and National Cancer Institute co-op groups indicated wide adoption of mitigation strategies with minimal perceived impact on trial data integrity, supporting continued adoption of mitigation strategies for future clinical trials.
This is a joint project between ASCO and Friends.
In addition to presenting new data at ASCO, check out our events page for upcoming meetings related to these projects.
About Friends of Cancer Research
Friends of Cancer Research (Friends) is working to accelerate policy change, support groundbreaking science, and deliver new therapies to patients quickly and safely. We unite scientists, pharmaceutical companies, and policy makers with shared trust and guide them toward meaningful cooperation. This collaboration among partners from every healthcare sector ultimately drives advances in science, policy, and regulation that speed life-saving treatments to patients. For more information, please visit https://friendsofcancerresearch.org/.